{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:05:32Z","timestamp":1790111132516,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10549-026-08075-4","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:08:47Z","timestamp":1790107727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective, observational cohort study of treatment patterns and outcomes among patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States following endocrine therapy"],"prefix":"10.1007","volume":"219","author":[{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MK","family":"Rehnquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Sadetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Verret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin","family":"Cinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoleta","family":"Sjekloca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"8075_CR1","unstructured":"National Institutes of Health, National Cancer Institute. National Institutes of Health, National Cancer Institute, Surveillance, Epidemiology, and End Results Program cancer stat facts: female breast cancer subtypes. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html"},{"key":"8075_CR2","doi-asserted-by":"publisher","first-page":"e2461067","DOI":"10.1001\/jamanetworkopen.2024.61067","volume":"8","author":"PPM Berton Giachetti","year":"2025","unstructured":"Berton Giachetti PPM, Morganti S, Gandini S et al (2025) Survival following CDK4\/6 inhibitor therapy for hormone receptor-positive, ERBB2-negative metastatic breast cancer. JAMA Netw Open 8:e2461067. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.61067","journal-title":"JAMA Netw Open"},{"key":"8075_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","volume":"25","author":"P Neven","year":"2023","unstructured":"Neven P, Fasching PA, Chia S et al (2023) Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res 25:103. https:\/\/doi.org\/10.1186\/s13058-023-01701-9","journal-title":"Breast Cancer Res"},{"key":"8075_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A et al (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5. https:\/\/doi.org\/10.1038\/s41523-018-0097-z","journal-title":"NPJ Breast Cancer"},{"key":"8075_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","volume":"28","author":"YS Lu","year":"2022","unstructured":"Lu YS, Im SA, Colleoni M et al (2022) Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res 28:851\u2013859. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3032","journal-title":"Clin Cancer Res"},{"key":"8075_CR6","doi-asserted-by":"publisher","first-page":"102670","DOI":"10.1016\/j.ctrv.2023.102670","volume":"123","author":"K Jhaveri","year":"2024","unstructured":"Jhaveri K, Marme F (2024) Current and emerging treatment approaches for hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer. Cancer Treat Rev 123:102670. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102670","journal-title":"Cancer Treat Rev"},{"key":"8075_CR7","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz MP, Toi M, Huober J et al (2024) Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol 35:718\u2013727. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.013","journal-title":"Ann Oncol"},{"key":"8075_CR8","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.annonc.2025.07.017","volume":"36","author":"D Trapani","year":"2025","unstructured":"Trapani D, Martins-Branco D, Curigliano G, Gennari A, Pentheroudakis G, Harbeck N, clinicalguidelines@esmo.org EGCEa (2025) Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline. Ann Oncol 36:1414\u20131418. https:\/\/doi.org\/10.1016\/j.annonc.2025.07.017","journal-title":"Ann Oncol"},{"key":"8075_CR9","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1200\/JCO.24.00248","volume":"42","author":"HJ Burstein","year":"2024","unstructured":"Burstein HJ, DeMichele A, Fallowfield L et al (2024) Endocrine and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer-capivasertib-fulvestrant: ASCO rapid recommendation update. J Clin Oncol 42:1450\u20131453. https:\/\/doi.org\/10.1200\/JCO.24.00248","journal-title":"J Clin Oncol"},{"key":"8075_CR10","doi-asserted-by":"publisher","first-page":"104634","DOI":"10.1016\/j.critrevonc.2025.104634","volume":"208","author":"R Torrisi","year":"2025","unstructured":"Torrisi R, Gerosa R, Miggiano C, Saltalamacchia G, Benvenuti C, Santoro A (2025) Beyond failure of endocrine-based therapies in HR+\/HER2 negative advanced breast cancer: What before chemotherapy? A glimpse into the future. Crit Rev Oncol Hematol 208:104634. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104634","journal-title":"Crit Rev Oncol Hematol"},{"key":"8075_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.breast.2021.02.015","volume":"57","author":"D Basile","year":"2021","unstructured":"Basile D, Gerratana L, Corvaja C et al (2021) First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: a real-world study. Breast 57:104\u2013112. https:\/\/doi.org\/10.1016\/j.breast.2021.02.015","journal-title":"Breast"},{"key":"8075_CR12","doi-asserted-by":"publisher","first-page":"102924","DOI":"10.1016\/j.ctrv.2025.102924","volume":"135","author":"TK Sahin","year":"2025","unstructured":"Sahin TK, Rizzo A, Guven DC, Aksoy S (2025) Post-progression treatment options after CDK4\/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer. Cancer Treat Rev 135:102924. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102924","journal-title":"Cancer Treat Rev"},{"key":"8075_CR13","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.3390\/cancers15072015","volume":"15","author":"A Mittal","year":"2023","unstructured":"Mittal A, Molto Valiente C, Tamimi F, Schlam I, Sammons S, Tolaney SM, Tarantino P (2023) Filling the gap after CDK4\/6 inhibitors: novel endocrine and biologic treatment options for metastatic hormone receptor positive breast cancer. Cancers (Basel) 15:2015. https:\/\/doi.org\/10.3390\/cancers15072015","journal-title":"Cancers (Basel)"},{"key":"8075_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.clbc.2021.10.007","volume":"22","author":"C Twelves","year":"2022","unstructured":"Twelves C, Bartsch R, Ben-Baruch NE, Borstnar S, Dirix L, Tesarova P, Timcheva C, Zhukova L, Pivot X (2022) The place of chemotherapy in the evolving treatment landscape for patients with HR-positive\/HER2-negative MBC. Clin Breast Cancer 22:223\u2013234. https:\/\/doi.org\/10.1016\/j.clbc.2021.10.007","journal-title":"Clin Breast Cancer"},{"key":"8075_CR15","doi-asserted-by":"publisher","first-page":"103691","DOI":"10.1016\/j.esmoop.2024.103691","volume":"9","author":"SM Tolaney","year":"2024","unstructured":"Tolaney SM, Punie K, Carey LA et al (2024) Real-world treatment patterns and outcomes in patients with HR+\/HER2- metastatic breast cancer treated with chemotherapy in the United States. ESMO Open 9:103691. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103691","journal-title":"ESMO Open"},{"key":"8075_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"8075_CR17","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marme F et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402:1423\u20131433. https:\/\/doi.org\/10.1016\/S0140-6736(23)01245-X","journal-title":"Lancet"},{"key":"8075_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1200\/OP.2025.21.10_suppl.216","volume":"21","author":"EL Mayer","year":"2025","unstructured":"Mayer EL, Betts KA, Ramasubramanian R, Pham T, Chen C (2025) First-line endocrine-based therapy in metastatic breast cancer: real-world evidence on patient characteristics, treatment patterns, and survival outcomes. JCO Oncol Pract 21:216. https:\/\/doi.org\/10.1200\/OP.2025.21.10_suppl.216","journal-title":"JCO Oncol Pract"},{"key":"8075_CR19","unstructured":"Flatiron Health. Database characterization guide. https:\/\/flatiron.com\/database-characterization. Accessed 3 February 2026"},{"key":"8075_CR20","unstructured":"World Medical Association. Declaration of Helsinki. https:\/\/www.wma.net\/what-we-do\/medical-ethics\/declaration-of-helsinki\/. Accessed 3 February 2026"},{"key":"8075_CR21","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2026) ICH harmonised guideline guideline for good clinical practice E6(R3). Final version. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf. Accessed 3 February"},{"key":"8075_CR22","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1158\/1538-7445.AM2022-4089","volume":"82","author":"MA Izano","year":"2022","unstructured":"Izano MA, Teka M, Johanson C et al (2022) Time to treatment discontinuation and time to next treatment as proxies of real-world progression-free survival in breast cancer patients. Cancer Res 82:4089. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-4089","journal-title":"Cancer Res"},{"key":"8075_CR23","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1200\/JCO.2022.40.16_suppl.6520","volume":"40","author":"C Labaki","year":"2022","unstructured":"Labaki C, Bakouny Z, Sanglier T et al (2022) Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: a real-world experience. J Clin Oncol 40:6520. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.6520","journal-title":"J Clin Oncol"},{"key":"8075_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-020-05838-5","volume":"184","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Dieras V, Cortes J et al (2020) Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1. Breast Cancer Res Treat 184:161\u2013172. https:\/\/doi.org\/10.1007\/s10549-020-05838-5","journal-title":"Breast Cancer Res Treat"},{"key":"8075_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s10637-025-01525-8","volume":"43","author":"T Najdi","year":"2025","unstructured":"Najdi T, Awad L, Chartouni A, Soueidy C, Kourie H (2025) Navigating antibody\u2013drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies. Invest New Drugs 43:466\u2013503. https:\/\/doi.org\/10.1007\/s10637-025-01525-8","journal-title":"Invest New Drugs"},{"key":"8075_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.20892\/j.issn.2095-3941.2022.0702","volume":"20","author":"X Wang","year":"2023","unstructured":"Wang X, Yue J, Kang Y et al (2023) Combined chemo-endocrine therapy as a potential new option for HR+\/HER2- advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine. Cancer Biol Med 20:287\u2013296. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2022.0702","journal-title":"Cancer Biol Med"},{"key":"8075_CR27","doi-asserted-by":"publisher","first-page":"PS2","DOI":"10.1158\/1557-3265.SABCS25-PS2-02-20","volume":"32","author":"V Kaklamani","year":"2026","unstructured":"Kaklamani V, Valliant S, Hunter S, Tymejczyk O, Yu A, Earla P, Mehta S, Pang E (2026) Treatment patterns and clinical outcomes following progression on first-line ET\u2009+\u2009CDK4\/6i among patients with HR+\/HER2\u2009\u2013\u2009metastatic breast cancer (mBC) in the US. Clin Cancer Res 32:PS2\u2013P02. https:\/\/doi.org\/10.1158\/1557-3265.SABCS25-PS2-02-20","journal-title":"Clin Cancer Res"},{"key":"8075_CR28","first-page":"28","volume":"38","author":"S Mehta","year":"2024","unstructured":"Mehta S, Zimmerman-Savill K, Wang P, Pathak P, Lam C, Kwong J, Feinberg B (2024) Treatment patterns and clinical outcomes following endocrine resistance among HER2-low metastatic breast cancer patients\u2014 retrospective observational study. Oncology 38:28","journal-title":"Oncology"},{"key":"8075_CR29","doi-asserted-by":"publisher","first-page":"PS1","DOI":"10.1158\/1557-3265.SABCS25-PS1-11-03","volume":"32","author":"T Traina","year":"2026","unstructured":"Traina T, Rossi C, Levesque-Leroux M, Tardif-Samson A, Gagnon-Sanschagrin P, Gu\u00e9rin A, Vlassak S, Guan V, Salcedo J (2026) Real-world treatment patterns and overall survival in patients with HR+\/HER2- metastatic breast cancer treated with chemotherapy following endocrine therapy in the US. Clin Cancer Res 32:PS1\u201311. https:\/\/doi.org\/10.1158\/1557-3265.SABCS25-PS1-11-03","journal-title":"Clin Cancer Res"},{"key":"8075_CR30","unstructured":"American Cancer Society. Breast cancer facts & figures (2024\u20132025). https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/2024\/breast-cancer-facts-and-figures-2024.pdf. Accessed 3 February 2026"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08075-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08075-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08075-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:08:49Z","timestamp":1790107729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08075-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8075"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08075-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with principles consistent with the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice (ICH-GCP) and applicable legislation on observational studies.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective, observational study of de-identified data from an existing dataset of electronic health record data from the United States did not involve direct enrollment of any patients and personal identifiable data were not collected; informed consent forms were therefore not collected.","order":2,"name":"Ethics","label":"Consent to participate and publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae and reflecting non-conflict of interest. The request proposal must also include a statistician. Approval of such requests is at Gilead Science\u2019s discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datasharing@gilead.com.","order":3,"name":"Ethics","label":"Data sharing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Presented at the San Antonio Breast Cancer Symposium; December 9\u201312, 2025, San Antonio, Texas, USA.","order":4,"name":"Ethics","label":"Prior presentation","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JOS reports consulting fees from AADI Bioscience, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, BioNTech, Bristol Myers Squibb (BMS), Daiichi Sankyo, Duality, Eisai, Eli Lilly, Ellipses, Exact Sciences, G1 Therapeutics, Genentech, Gilead Sciences, Inc., Guardant Health, Hibercell, Jazz Pharmaceuticals, Johnson & Johnson, Menarini-Stemline, Merck, Mersana, Natera, Novartis, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, RayzeBio, Roche, Sanofi, Seagen, Stemline Therapeutics, Summitt Therapeutics, Tempus, TerSera Therapeutics; and honoraria from AADI Bioscience, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, BioNTech, BMS, Daiichi Sankyo, Duality, Eisai, Eli Lilly, Ellipses, Exact Sciences, G1 Therapeutics, Genentech, Gilead Sciences, Inc., Guardant Health, Hibercell, Jazz Pharmaceuticals, Johnson & Johnson, Menarini-Stemline, Merck, Mersana, Natera, Novartis, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, RayzeBio, Roche, Sanofi, Seagen, Stemline Therapeutics, Summitt Therapeutics, Tempus, TerSera Therapeutics. RN reports grants or contracts from Arvinas, AstraZeneca, BMS, Corcept Therapeutics, Genentech\/Roche, Gilead Sciences, Inc., Jazz Pharmaceuticals, Merck, Mabwell, Novartis, OBI Pharmaceuticals, Pfizer, Relay, Sun Pharmaceuticals, Taiho; and consulting fees from Arvinas, AstraZeneca, Corcept Therapeutics, Daiichi Sankyo, Eli Lilly, Exact Sciences, GE, Gilead Sciences, Inc., Guardant Health Mabwell, Merck, Moderna, Novartis, Pfizer, Stemline, Summit Therapeutics. PS reports grants or contracts from Gilead Sciences Inc., Merck, Novartis; royalties from UpToDate; and advisory board attendance with AstraZeneca, Daiichi Sankyo, Eli Lilly, Menarini-Stemline, Natera, Novartis, Pfizer. MKR, NaS WV, PC, NiS, and LN report employment and stock ownership with Gilead Sciences, Inc.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"19"}}